Hormone Related Cancers Program

11.0翻译后摘要：激素相关的癌症（HRC）计划 马里兰州大学人权方案的首要目标是 综合癌症中心（UMGCCC）是为了降低癌症的发病率和死亡率， 相关组织。为了实现这一使命，该方案侧重于三个具体目标：目标1： 介导先天性和获得性抗性的乳腺癌相关癌症中的靶点， 了解癌症如何抵抗激素治疗或在复发期间产生耐药性;目标2：目标 调节癌症干细胞和促进转移的机制，重点是定义和 目标3：制定改善癌症复发的策略 诊断，通知治疗，并评估治疗反应，以应用新技术， 癌症成像和加速肿瘤药物反应分析，以实现精准医疗。要实现这三个 的目标，人权委员会成员的支持，合作者和资源，在其他UMGCCC计划， 以及卓越的共享服务。人权委员会计划有46个成员，其中包括30个正式成员和16个 准会员，主要在乳腺、前列腺和乳腺癌领域进行基础、转化和临床研究， 卵巢癌，每年直接资助870万美元（总计1100万美元），其中340万美元（39%）来自NCI 以及其他同行评审来源的260万美元。人权委员会计划成员每年从 非同行审查的资金来源。在此资助期间，人权理事会成员撰写了506份与癌症有关的报告， 出版物，其中17%来自方案内，28%来自方案间，6%来自方案内， 项目间合作; 60%的出版物包括与外部研究人员的合作， 这反映了人权委员会方案在全国的巨大影响。HRC计划成员管理着众多临床 审判在此期间，HRC计划招募了1，412名患者进行临床试验，其中包括213名患者。 干预性试验（200例治疗性干预性试验）和1，199例非干预性试验患者。41.5%的 病人是代表性不足的少数民族，反映了集水区的人口统计。研究 人权委员会成员的方案利用所有UMGCCC共享服务。人权委员会方案与 其他四个UMGCCC研究计划，并从事社区外展和参与，以确定和 解决集水区的癌症研究优先事项。

11.0 Abstract: Hormone Related Cancers (HRC) Program The overarching goal of the HRC Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is to reduce the morbidity and mortality of cancers that arise from hormone-related tissues. To achieve this mission, the program focuses on three specific aims: Aim 1: Identify targets in hormone-related cancers that mediate innate and acquired resistance improves the understanding of how cancers resist hormonal therapies or develop resistance during recurrence; Aim 2: Target mechanisms that regulate cancer stem cells and promote metastasis, with a focus on defining and therapeutically targeting mechanisms of cancer recurrence; and Aim 3: Develop strategies to improve diagnosis, inform treatment, and evaluate treatment response to apply new technologies that advance cancer imaging and accelerate analysis of tumor drug response for precision medicine. To achieve these three aims, HRC members are supported by collaborators and resources throughout other UMGCCC programs as well as exceptional shared services. The HRC Program has 46 members, including 30 full members and 16 associate members, who conduct basic, translational, and clinical research chiefly in breast, prostate, and ovarian cancer with $8.7 million direct annual funding ($11.0 million total), including $3.4 million (39%) from NCI and $2.6 million from other peer-reviewed sources. HRC Program members receive $2.7 million annually from non–peer-reviewed funding sources. During this funding period, HRC members authored 506 cancer-related publications, of which 17% resulted from intraprogrammatic, 28% from interprogrammatic, 6% from intra and interprogrammatic collaborations; and 60% of publications include collaborations with external investigators, reflecting the high national impact of the HRC Program. HRC Program members manage numerous clinical trials. During this grant period, the HRC Program enrolled 1,412 patients on clinical trials, including 213 on interventional trials (200 therapeutic interventional), and 1,199 patients on non-interventional trials. 41.5% of patients were underrepresented minorities, reflecting the demographics of the catchment area. The research programs of HRC members utilize all of the UMGCCC shared services. The HRC Program collaborates with the other four UMGCCC Research Programs and engages community outreach and engagement to identify and address the cancer research priorities of the catchment area.